Intra-Cellular Therapies Q1: $144.8M CAPLYTA sales (+53% YoY), loss narrows; Ph3 MDD success

Intra-Cellular Therapies, Inc.

2024-Q1 EPS reported -$0.16 revenue$144,866,000

Net product sales of CAPLYTA $144.8M, up 53% from $94.7M YoY; net loss $15.2M vs $44.1M.
Positive Phase 3 Study 501 results: lumateperone adjunctive MDD met primary (MADRS, p<0.0001) and key secondary endpoints.
FY 2024 guidance reiterated: CAPLYTA sales $645-$675M, SG&A $450-$480M, R&D $215-$240M.
Completed $543M net public offering of ~7.9M shares in April 2024; cash $477.4M at Q1 end.
Expect to report Study 502 topline results late Q2 2024; sNDA filing planned H2 2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Intra-Cellular Therapies, Inc. reported the first quarter ended March 31, 2024 results: revenue $144.9 million, net income Net loss for the first quarter of 2024 was $15.2 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $144.9 million
Net income: Net loss for the first quarter of 2024 was $15.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenues were $144.9 million for the first quarter of 2024, compared to $95.3 million for the same period in 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-132586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.